In 308 patients with gout and hyperuricaemia in the Netherlands, a treat-to-target urate strategy achieved more remission at months 18-24 than symptom-driven management (39.4% vs 24.0%; difference 15.4 points, p=0.024), with no excess adverse events.
RCTn = 308
Moses et al. A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomised controlled trial